Clinical Significance of CTNNB1 Mutation and Wnt Pathway Activation in Endometrioid Endometrial Carcinoma

• Published in: JNCI : Journal of the National Cancer Institute Vol. 106; no. 9; p. 1
• Main Authors: Liu, Yuexin, Patel, Lalit, Mills, Gordon B., Lu, Karen H., Sood, Anil K., Ding, Li, Kucherlapati, Raju, Mardis, Elaine R., Levine, Douglas A., Shmulevich, Ilya, Broaddus, Russell R., Zhang, Wei
• Format: Journal Article
• Language: English
• Published: United States Oxford Publishing Limited (England) 01.09.2014; Oxford University Press
• Subjects: Adult; beta Catenin - genetics; Biomarkers, Tumor - genetics; Cancer; Carcinoma, Endometrioid - genetics; Carcinoma, Endometrioid - metabolism; Carcinoma, Endometrioid - mortality; Carcinoma, Endometrioid - pathology; Endometrial Neoplasms - genetics; Endometrial Neoplasms - metabolism; Endometrial Neoplasms - mortality; Endometrial Neoplasms - pathology; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes; Humans; Kaplan-Meier Estimate; Mutation; Neoplasm Grading; Neoplasm Staging; Ribonucleic acid; RNA; Tissue Array Analysis; Transcriptome; Tumors; Wnt Signaling Pathway
• ISSN: 0027-8874; 1460-2105; 1460-2105
• DOI: 10.1093/jnci/dju245

Endometrioid endometrial carcinoma (EEC) is the most common form of endometrial carcinoma. The heterogeneous clinical course of EEC is an obstacle to individualized patient care. We performed an integrated analysis on the multiple-dimensional data types including whole-exome and RNA sequencing, RPPA profiling, and clinical data from 271 EEC cases in The Cancer Genome Atlas (TCGA) to identify molecular fingerprints that may account for this clinical heterogeneity. Significance analysis of microarray was used to identify marker genes of each subtype that were subject to pathway analysis. Association of molecular subtypes with clinical features and mutation data was analyzed with the Mann Whitney, Chi-square, Fisher's exact, and Kruskal-Wallis tests. Survival analysis was evaluated with log-rank test. All statistical tests were two-sided. Four transcriptome subtypes with distinct clinicopathologic characteristics and mutation spectra were identified from the TCGA dataset and validated in an independent sample cohort of 184 EEC cases. Cluster II consisted of younger, obese patients with low-grade EEC but diminished survival. CTNNB1 exon 3 mutations were present in 87.0% (47/54) of Cluster II (P < .001) that exhibited a low overall mutation rate; this was statistically significantly associated with Wnt/β-catenin signaling activation (P < .001). High expression levels of CTNNB1 (P = .001), MYC (P = .01), and CCND1 (P = .01) were associated with poorer overall survival in low-grade EEC tumors. CTNNB1 exon 3 mutations are likely a driver that characterize an aggressive subset of low-grade and low-stage EEC occurring in younger women.